Serum miR-20a is a promising biomarker for gastric cancer

  • Authors:
    • Ruirui Yang
    • Yun Fu
    • Ying Zeng
    • Mengqin Xiang
    • Yufang Yin
    • Li Li
    • Haifan Xu
    • Jing Zhong
    • Xi Zeng
  • View Affiliations

  • Published online on: February 20, 2017     https://doi.org/10.3892/br.2017.862
  • Pages: 429-434
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is a common type of cancer, particularly in China. Numerous studies have demonstrated that circulating microRNAs (miRNAs) have potential applications as noninvasive biomarkers for cancer diagnosis and prognosis. Microarray-based serum miRNA profiling was performed on the serum of 12 paired pre- and post-operative GC patients to screen differentially expressed serum miRNAs. Twelve different serum miRNAs between pre- and post‑operative GC patients were identified. Those miRNAs were verified by real-time quantitative polymerase chain reaction in 110 paired pre- and post-operative serum samples from 55 GC patients. miR-20a was confirmed and demonstrated potential as a GC-associated biomarker. Furthermore, the levels of serum miR-20a were significantly different between GC, nasopharyngeal cancer, colorectal carcinoma, breast cancer and non-cancerous controls. In addition, it was found that serum miR-20a levels correlated with age, tumor stage, differentiated degree and lymph node metastasis in GC. Survival analysis indicated that GC patients with elevated levels of serum miR-20a had poor survival. Thus, serum miR-20a may serve as a molecular marker for diagnosis, evaluating therapeutic efficacy and prognosis, as well as monitoring recurrence in GC patients.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Hou X, Zhang M and Qiao H: Diagnostic significance of miR-106a in gastric cancer. Int J Clin Exp Pathol. 8:13096–13101. 2015.PubMed/NCBI

3 

Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, et al: Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 7:e463672012. View Article : Google Scholar : PubMed/NCBI

4 

Schwarzenbach H, Nishida N, Calin GA and Pantel K: Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Bianchi F: Lung cancer early detection: the role of circulating microRNAs. EBioMedicine. 2:1278–1279. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Mirzaei HR, Sahebkar A, Mohammadi M, Yari R, Salehi H, Jafari MH, Namdar A, Khabazian E, Jaafari MR and Mirzaei H: Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr Pharm Des. 22:5257–5269. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Vickers KC and Remaley AT: Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol. 23:91–97. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A and Chang DH: Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 6:22–33. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, et al: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y and Kusunoki M: Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 19:744–753. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Cheng G: Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 81:75–93. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Fonsato V, Collino F, Herrera MB, Cavallari C, Deregibus MC, Cisterna B, Bruno S, Romagnoli R, Salizzoni M, Tetta C, et al: Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs. Stem Cells. 30:1985–1998. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, Xie H, Xu Y and Zeng X: U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 454:210–214. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer-Verlag; New York, NY: 2009

15 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, Huang H, Li S and Zhao J: miRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI

17 

Babu KR and Muckenthaler MU: miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl). 94:347–359. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Safari A, Seifoleslami M, Yahaghi E, Sedaghati F and Khameneie MK: RETRACTED ARTICLE: Upregulation of miR-20a and miR-10a expression levels act as potential biomarkers of aggressive progression and poor prognosis in cervical cancer. Tumour Biol. Oct 1–2015.(Epub ahead of print).

19 

Zhang Y, Zheng L, Ding Y, Li Q, Wang R, Liu T, Sun Q, Yang H, Peng S, Wang W, et al: miR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Sokolova V, Fiorino A, Zoni E, Crippa E, Reid JF, Gariboldi M and Pierotti MA: The effects of miR-20a on p21: two mechanisms blocking growth arrest in TGF-β-responsive colon carcinoma. J Cell Physiol. 230:3105–3114. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Azizian A, Kramer F, Jo P, Wolff HA, Beißbarth T, Skarupke R, Bernhardt M, Grade M, Ghadimi BM and Gaedcke J: Preoperative prediction of lymph node status by circulating mir-18b and mir-20a during chemoradiotherapy in patients with rectal cancer. World J Surg. 39:2329–2335. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Qiang XF, Zhang ZW, Liu Q, Sun N, Pan LL, Shen J, Li T, Yun C, Li H and Shi LH: miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J Cell Biochem. 115:1269–1276. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 47:784–791. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J, Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB. Tumour Biol. 37:1261–1269. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2017
Volume 6 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, R., Fu, Y., Zeng, Y., Xiang, M., Yin, Y., Li, L. ... Zeng, X. (2017). Serum miR-20a is a promising biomarker for gastric cancer. Biomedical Reports, 6, 429-434. https://doi.org/10.3892/br.2017.862
MLA
Yang, R., Fu, Y., Zeng, Y., Xiang, M., Yin, Y., Li, L., Xu, H., Zhong, J., Zeng, X."Serum miR-20a is a promising biomarker for gastric cancer". Biomedical Reports 6.4 (2017): 429-434.
Chicago
Yang, R., Fu, Y., Zeng, Y., Xiang, M., Yin, Y., Li, L., Xu, H., Zhong, J., Zeng, X."Serum miR-20a is a promising biomarker for gastric cancer". Biomedical Reports 6, no. 4 (2017): 429-434. https://doi.org/10.3892/br.2017.862